residences the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age [see Use in Specific Populations ( 8.5 ) ]. Pediatric: Pharmacokinetic data in the pediatric population are not available. Gender: In a single dose pharmacokinetic study with Altoprev instructional materials
most usually Immediate-Release In a study with lovastatin immediate-release which included 16 elderly patients between 70-78 years of age who received lovastatin immediate-release 80 mg/day power
EmoticonEmoticon